The second ones are the FDA approved anaplastic lymphoma kinase (ALK) inhibitors (e.g., crizotinib and ceritinib), which show positive effects in tumours harbouring ALK gene rearrangements [92,93]. The gene discussed is ALK; the disease is neoplasm.